Occupational exposure to Cr(VI) in Finland in 1980-2016 and related lung cancer risk assessment.


Journal

Regulatory toxicology and pharmacology : RTP
ISSN: 1096-0295
Titre abrégé: Regul Toxicol Pharmacol
Pays: Netherlands
ID NLM: 8214983

Informations de publication

Date de publication:
Dec 2022
Historique:
received: 30 12 2021
revised: 27 09 2022
accepted: 07 10 2022
pubmed: 15 10 2022
medline: 30 11 2022
entrez: 14 10 2022
Statut: ppublish

Résumé

Occupational exposure to hexavalent chromium [Cr(VI)], a known lung carcinogen, remains a relevant concern. When performing exposure assessment for risk assessment, biomonitoring is an important tool, reflecting actual internal exposure of workers. Here, we present total urinary chromium (U-Cr) biomonitoring data from several occupational sectors, spanning 1980-2016 (n > 42,000). Based on these data, we estimated lifelong (40-year) occupational lung cancer risks in the Cr-plating and welding sectors. We used published regression formulas to relate internal (U-Cr) and external Cr(VI) inhalation exposures, allowing risk assessment based on a published lung cancer dose-response. Generally, measured U-Cr levels decreased considerably over the study period. The overall highest U-Cr P95 levels (representing realistic worst-case) were measured in the interval 1980-1989 in casters, maintenance workers and welders (40-45 μg/L). By the interval 2010-2016, the U-Cr P95 had decreased to ≤9.5 μg/L in all studied sectors. Lifelong external Cr(VI) exposure estimation for 1980-2019 was 0.16-0.32 mg/m

Identifiants

pubmed: 36240957
pii: S0273-2300(22)00163-5
doi: 10.1016/j.yrtph.2022.105276
pii:
doi:

Substances chimiques

chromium hexavalent ion 18540-29-9
Chromium 0R0008Q3JB

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

105276

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Selma Mahiout (S)

Finnish Institute of Occupational Health (FIOH), Helsinki, Finland. Electronic address: selma.mahiout@ttl.fi.

Mirja Kiilunen (M)

Finnish Institute of Occupational Health (FIOH), Helsinki, Finland.

Theo Vermeire (T)

National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.

Susana Viegas (S)

NOVA National School of Public Health, Public Health Research Centre, Universidade NOVA de Lisboa, Portugal; Portugal Comprehensive Health Research Center (CHRC), Portugal; H&TRC- Health & Technology Research Center, ESTeSL- Escola Superior de Tecnologia da Saúde, Instituto Politécnico de Lisboa, Portugal.

Marjolijn Woutersen (M)

National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.

Tiina Santonen (T)

Finnish Institute of Occupational Health (FIOH), Helsinki, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH